System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Published Erratum Ahead of print

PubMed: 42901991 DOI: 10.1038/s41591-026-04757-0

Author Correction: FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

Nat Med

Authors: Adam D Cohen, Joshua Richter, Suzanne Trudel, Alexander Lesokhin, Jacob P Laubach, Sheeba K Thomas, Simon J Harrison, Luciano J Costa, Andrew Spencer, Rafael Fonseca, Peter A Forsberg, Jesus G Berdeja, Rayan Kaedbey, Nizar J Bahlis, Paula Rodriguez-Otero, Maria-Victoria Mateos, Tulika Tyagi, Divya Samineni, Wenyu Liu, Rin Nakamura, Voleak Choeurng, Chihunt Wong, James Cooper, Amrita Krishnan

Affiliations

  • Abramson Cancer Center and University of Pennsylvania, Philadelphia, PA, USA.
  • Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Princess Margaret Cancer Centre and University of Toronto, Toronto, Ontario, Canada.
  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, USA.
  • Dana-Farber Cancer Institute, Boston, MA, USA.
  • The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Peter MacCallum Cancer Centre, Sir Peter MacCallum Department of Oncology, Melbourne University, and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
  • Alfred Health-Monash University, Melbourne, Victoria, Australia.
  • Mayo Clinic in Arizona, Phoenix, AZ, USA.
  • University of Colorado School of Medicine, Aurora, CO, USA.
  • Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN, USA.
  • Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
  • Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Alberta, Canada.
  • Clínica Universidad de Navarra, Pamplona, Spain.
  • Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Centro de Investigación del Cáncer (CIC) and Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Salamanca, Spain.
  • Genentech, Inc. South San Francisco, CA, USA.
  • City of Hope Duarte, Duarte, CA, USA.

MeSH

Molecular Biology, Multiple Myeloma